Bezos, Elon Musk and Zuckerberg Betting Big on S.C.G.
The "Black Box" Device Bringing the Age of the Smartphone to an End.
Learn More
Douglas M. Lankler, insider at Pfizer
Douglas M. Lankler Insider Alerts

Get notified the next time Douglas M. Lankler buys or sells Pfizer stock. Enter your email address below to get our daily insider buying and selling report.

Douglas M. Lankler Insider Information

EVP of Pfizer
Doug Lankler joined Pfizer in 1999 and currently serves as general counsel. Prior to being named general counsel, Doug was Pfizer's chief compliance and risk officer, a role he assumed in 2006.

Prior to joining the company, Doug was with the United States Department of Justice as an Assistant U.S. Attorney in the Southern District of New York. Doug was a recipient of the United States Attorney General's Distinguished Service Award.

Doug graduated from the State University of New York at Albany and Cornell Law School. He and his wife, Jill, have three children and reside in Larchmont, N.Y.

What is Douglas M. Lankler's net worth?

The estimated net worth of Douglas M. Lankler is at least $7.32 million as of April 29th, 2020. Mr. Lankler owns 135,375 shares of Pfizer stock worth more than $7,317,019 as of January 20th. This net worth approximation does not reflect any other investments that Mr. Lankler may own. Learn More.

How do I contact Douglas M. Lankler?

The corporate mailing address for Mr. Lankler and other Pfizer executives is 235 EAST 42ND STREET, NEW YORK NY, 10017. Pfizer can also be reached via phone at (212) 733-2323.

Has Douglas M. Lankler been buying or selling shares of Pfizer?

Douglas M. Lankler has not been actively trading shares of Pfizer during the past quarter. Most recently, Douglas M. Lankler sold 40,000 shares of the business's stock in a transaction on Friday, November 26th. The shares were sold at an average price of $54.37, for a transaction totalling $2,174,800.00.

Who are Pfizer's active insiders?

Pfizer's insider roster includes Jennifer Damico (SVP), Jennifer Damico (SVP), Douglas Lankler (EVP), Alexander Mackenzie (EVP), and John Young (Insider).

Are insiders buying or selling shares of Pfizer?

In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 238,021 shares worth more than $12,217,419.90. The most recent insider tranaction occured on December, 2nd when EVP Alexander R Mackenzie sold 41,360 shares worth more than $2,244,193.60. Insiders at Pfizer own 0.1 % of the company.

Information on this page was last updated on 12/2/2021.

Douglas M. Lankler Insider Trading History at Pfizer

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/26/2021Sell40,000$54.37$2,174,800.00View SEC Filing Icon  
4/29/2020Sell65,000$37.85$2,460,250.00135,375View SEC Filing Icon  
2/1/2019Sell5,000$42.75$213,750.0083,592View SEC Filing Icon  
1/30/2019Sell38,800$41.19$1,598,172.0083,592View SEC Filing Icon  
3/13/2018Sell50,000$36.89$1,844,500.00133,057View SEC Filing Icon  
5/4/2016Sell29,700$33.69$1,000,593.00124,920View SEC Filing Icon  
See Full Table

Douglas M. Lankler Buying and Selling Activity at Pfizer

This chart shows Douglas M Lankler's buying and selling at Pfizer by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pfizer Company Overview

Pfizer logo
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More

Today's Range

Now: $54.05
Low: $53.07
High: $54.52

50 Day Range

MA: $54.75
Low: $49.60
High: $61.25

2 Week Range

Now: $54.05
Low: $33.36
High: $61.71


34,833,765 shs

Average Volume

37,716,852 shs

Market Capitalization

$303.38 billion

P/E Ratio


Dividend Yield



Buy Live Nation (LYV) Immediately
Wall Street legend who helped create America’s stock-rating system says this stock could soon be rated a “Strong Buy” at every bank in New York City and Boston. “It’s all part of the biggest prediction of my 50-year career on Wall Street,” he says. “A massive and surprising new transition that could determine the next group of millionaires.”
Click here to learn more.